Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
Nicole Verdun(Center for Biologics Evaluation and Research), Peter Marks(Center for Biologics Evaluation and Research)
Cited by 257
Related Papers
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
|Journal of Clinical Investigation|2020|485
Safety Update
|Mayo Clinic Proceedings|2020|432
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
|Clinical Cancer Research|2015|165
Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings
|Journal of Thrombosis and Haemostasis|2015|66